. 2016 Jun 9;115(1):34–39. doi: 10.1038/bjc.2016.155

Table 3. Competing-risks regression.

	Any metastasis						Hepatic metastasis
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
Validate	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Age >75	1.35	0.90–2.01	0.15	1.39	0.91–2.13	0.13	1.19	0.58–2.44	0.64	0.89	0.41–1.97	0.78
Sex	0.70	0.35–1.38	0.30	0.82	0.56–1.20	0.31	0.70	0.35–1.38	0.30	0.85	0.44–1.62	0.62
Body mass index >25	0.58	0.35–0.96	0.03				1.20	0.58–2.45	0.62
AST >35	1.86	1.08–3.21	0.03				0.31	0.04–2.29	0.25
ALT >35	1.59	0.95–2.66	0.08				1.72	0.72–4.11	0.22
Platelet count >100 000	1.8	0.24–13.5	0.57				0.58	0.08–4.07	0.59
CEA >5.0 ng ml⁻¹	1.87	1.29–2.71	<0.01				1.64	0.85–3.16	0.14
Diabetes mellitus	0.83	0.51–1.35	0.46				1.82	0.90–3.67	0.10
Hepatic virus	1.07	0.48–2.41	0.86				1.11	0.27–4.57	0.88
Hepatic fibrosis	1.57	0.88–2.81	0.13	0.87	0.42–1.82	0.72	1.07	0.33–3.47	0.92	2.86	0.98–12.8	0.02
Location
Right-sided colon	Ref	—	—				Ref	—	—
Left-sided colon	0.86	0.55–1.33	0.49				1.05	0.52–2.10	0.90
Rectum	1.68	1.08–2.62	0.02				0.70	0.27–1.82	0.46
Stage
I	Ref	—	—	Ref	—	—	Ref	—	—	Ref	—	—
II	11.9	3.68–38.7	<0.01	15.1	3.63–62.8	<0.01	11.9	3.68–38.7	<0.01	3.54	0.98–12.8	0.05
III	26.2	8.25–83.1	<0.01	43.6	10.7–177.9	<0.01	26.2	8.25–83.1	<0.01	7.03	2.12–23.3	<0.01
PS 0, 1/2, 3 and 4	1.55	0.81–2.99	0.19				0.42	0.06–3.08	0.39

Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; CEA=carcinoembryonic antigen; CI=confidence interval; HR=hazard ratio; PS=performance status; Ref=reference.